CUHK landmark study identifies key oncogenic driver miR-21 in pancreatic cancer Pioneer Nb-RIBOTAC technology for dual-targeted attack to eliminate tumours
September 24, 2026
September 24, 2026
SHATIN, Hong Kong, Sept. 24 -- The Chinese University of Hong Kong posted the following news release:
* * *
CUHK landmark study identifies key oncogenic driver miR-21 in pancreatic cancer Pioneer Nb-RIBOTAC technology for dual-targeted attack to eliminate tumours
*
Pancreatic cancer, also known as the silent killer, is among Hong Kong's five deadliest cancers, with a dismal five-year survival rate of less than 10%. A research team from the . . .
* * *
CUHK landmark study identifies key oncogenic driver miR-21 in pancreatic cancer Pioneer Nb-RIBOTAC technology for dual-targeted attack to eliminate tumours
*
Pancreatic cancer, also known as the silent killer, is among Hong Kong's five deadliest cancers, with a dismal five-year survival rate of less than 10%. A research team from the . . .
